Wall Street brokerages predict that Nabriva Therapeutics plc – (NASDAQ:NBRV) will post $1.48 million in sales for the current quarter, according to Zacks Investment Research. Four analysts have made estimates for Nabriva Therapeutics’ earnings, with the lowest sales estimate coming in at $1.00 million and the highest estimate coming in at $1.80 million. Nabriva Therapeutics posted sales of $2.31 million in the same quarter last year, which would indicate a negative year over year growth rate of 35.9%. The business is expected to announce its next quarterly earnings report on Friday, March 23rd.
According to Zacks, analysts expect that Nabriva Therapeutics will report full year sales of $1.48 million for the current year, with estimates ranging from $5.20 million to $6.00 million. For the next fiscal year, analysts expect that the company will report sales of $6.54 million per share, with estimates ranging from $2.90 million to $9.50 million. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that follow Nabriva Therapeutics.
Nabriva Therapeutics (NASDAQ:NBRV) last announced its earnings results on Thursday, November 9th. The biotechnology company reported ($0.66) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.07). Nabriva Therapeutics had a negative return on equity of 80.69% and a negative net margin of 985.30%.
A number of institutional investors and hedge funds have recently bought and sold shares of the business. Alyeska Investment Group L.P. bought a new stake in Nabriva Therapeutics in the third quarter valued at $5,724,000. Pura Vida Investments LLC bought a new stake in Nabriva Therapeutics in the third quarter valued at $3,481,000. Rubric Capital Management LP bought a new stake in Nabriva Therapeutics in the third quarter valued at $2,457,000. Nationwide Fund Advisors increased its stake in Nabriva Therapeutics by 4.6% in the second quarter. Nationwide Fund Advisors now owns 180,924 shares of the biotechnology company’s stock valued at $2,032,000 after purchasing an additional 7,924 shares in the last quarter. Finally, Royal Bank of Canada increased its stake in Nabriva Therapeutics by 19.6% in the second quarter. Royal Bank of Canada now owns 52,807 shares of the biotechnology company’s stock valued at $553,000 after purchasing an additional 8,650 shares in the last quarter. 57.12% of the stock is owned by hedge funds and other institutional investors.
Shares of Nabriva Therapeutics (NBRV) traded up $0.39 during midday trading on Thursday, reaching $6.39. 390,000 shares of the company were exchanged, compared to its average volume of 159,518. Nabriva Therapeutics has a fifty-two week low of $4.75 and a fifty-two week high of $14.10. The company has a market capitalization of $234.46 and a P/E ratio of -0.25.
COPYRIGHT VIOLATION NOTICE: “Nabriva Therapeutics plc – (NBRV) Expected to Post Quarterly Sales of $1.48 Million” was published by American Banking News and is the property of of American Banking News. If you are reading this story on another site, it was stolen and republished in violation of United States and international copyright and trademark legislation. The legal version of this story can be viewed at https://www.americanbankingnews.com/2018/01/18/nabriva-therapeutics-plc-nbrv-expected-to-post-quarterly-sales-of-1-48-million-3.html.
About Nabriva Therapeutics
Nabriva Therapeutics plc is a clinical stage biopharmaceutical company. The Company is engaged in engaged in the research and development of novel anti-infectives to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The Company’s medicinal chemistry has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations of its lead product candidate, lefamulin.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.